Drug Therapies for Fibromyalgia II
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 10802
Special Issue Editor
Interests: fibromyalgia; pain; potassium channels; drug design/discovery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In 1990 the American College of Rheumatology developed the criteria for the classification of fibromyalgia, a common complex persistent widespread pain condition. Treatment is often difficult, usually involving an empiric approach to drug therapy focused towards the individual symptoms of pain, fatigue, sleep disorder and cognitive dysfunction. Current medications are often limited in their effectiveness due to patients discontinuing use as a consequence of a high incidence of adverse effects. Drugs targeting a diverse range of molecular mechanisms have demonstrated modest improvement of health status in patients with fibromyalgia. Thus, the heterogeneity of fibromyalgia, suggesting existence of patient subgroups, central and peripheral aspects of the pathophysiology and a requirement of treatments targeting multiple molecular dysfunction need to be considered in the identification of new or improved therapies for the condition. We aim to invite original or review articles of preclinical and clinical findings contributing to the understanding of drug therapies for the treatment of fibromyalgia.
Dr. Kim Lawson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Related Special Issue: "Drug Therapies for the Treatment of Fibromyalgia"
Keywords
- Fibromyalgia
- Pain
- Fatigue
- Cognitive dysfunction
- Central sensitization
- Drug targets
- Novel molecular mechanisms
- Fibromyalgia animal models
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
